Analyst picks reform bill's biggest biotech winners

Rockefeller & Co analyst David Song sees a lot of healthcare companies coming out ahead in the event the new healthcare reform bill passes Congress. In particular, he cites Amgen and Alexion as two of the biotech industry's biggest winners. Both companies, he tells Barron's, have new drugs that will benefit from the bill's provision for marketing exclusivity. Report

Suggested Articles

Shorla Pharma picked up $8.3 million to push its cancer programs through U.S. regulatory approval and gear up for its first drug launch in 2021.

Nodthera bagged $55 million to get its lead asset through phase 1 and into proof-of-concept studies, and a second program into the clinic.

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.